moxalactam has been researched along with amikacin in 26 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 20 (76.92) | 18.7374 |
1990's | 2 (7.69) | 18.2507 |
2000's | 2 (7.69) | 29.6817 |
2010's | 2 (7.69) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Badur, S; Cagatay, AA; Carrër, A; Eraksoy, H; Nordmann, P; Poirel, L | 1 |
Girlich, D; Nordmann, P; Poirel, L | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Blaser, J | 1 |
Evagelopoulou, V; Giamarellou, H; Lelekis, M | 1 |
Blaser, J; Zinner, SH | 1 |
Baltch, AL; Bassey, C; Fanciullo, G; Smith, RP | 1 |
De Jongh, CA; Drusano, GL; Finley, RS; Joshi, JH; Moody, MR; Newman, KA; Salvatore, PC; Schimpff, SC; Tenney, JH; Thompson, BW | 1 |
Sabath, LD; Tack, KJ | 1 |
Hernández, NI; Nevárez, M; Ramírez-Ronda, CH; Rodríguez, JR | 1 |
Angel Montañés, M; Apraiz, D; Gamazo, C; Urra, E | 1 |
De Jongh, CA; Finley, RS; Fortner, CL; Moody, MR; Newman, KA; Salvatore, PC; Schimpff, SC; Standiford, HC; Wade, JC; Wiernik, PH | 1 |
McNamara, BT; Meyer, RD; Pasiecznik, KA | 1 |
Barriere, SL; Pons, VG; Wilson, CB | 1 |
Berk, SL; Verghese, A | 1 |
Bauer, D; Spohr, M; Traub, WH | 1 |
Meyer, RD; Pasiecznik, K | 1 |
Holloway, WJ; Reinhardt, JF | 1 |
Baker, CJ; Faingezicht, I; Feldman, WE; Kaplan, SL; McCracken, GH; Mize, S; Schaad, U; Threlkeld, N | 1 |
Bustamante, CI; Drusano, GL; Standiford, HC; Tatem, BA | 1 |
Alvarez, S; DeMaria, A; Klein, JO; McCabe, WR | 1 |
Mirrett, S; Reimer, LG; Reller, LB | 1 |
Barnes, RC; Champlin, RE; Gale, RP; Ho, WG; Winston, DJ; Young, LS | 1 |
Britten, J; Caplan, E; deJongh, CA; Finley, RS; Fortner, CL; Newman, KA; Schimpff, SC; Wade, JC; Wiernik, PH | 1 |
Bourquelot, P; Bouscary, D; Dreyfus, F; Paul, G; Picard, F; Tulliez, M; Varet, B | 1 |
4 trial(s) available for moxalactam and amikacin
Article | Year |
---|---|
A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amikacin; Bacterial Infections; Blood Bactericidal Activity; Blood Coagulation Disorders; Clinical Trials as Topic; Drug Hypersensitivity; Drug Synergism; Drug Therapy, Combination; Fever; Hearing Disorders; Humans; Infections; Kanamycin; Kidney Diseases; Microbial Sensitivity Tests; Middle Aged; Moxalactam; Neoplasms; Piperacillin; Random Allocation | 1986 |
Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amikacin; Bacterial Infections; Cephalosporins; Cephamycins; Child; Double-Blind Method; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Kanamycin; Male; Middle Aged; Moxalactam; Neoplasms; Penicillins; Prospective Studies; Random Allocation; Ticarcillin | 1982 |
Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation.
Topics: Amikacin; Ampicillin; Clinical Trials as Topic; Drug Therapy, Combination; Enterobacteriaceae Infections; Gram-Negative Bacteria; Humans; Infant, Newborn; Meningitis; Moxalactam; Prospective Studies; Radiography | 1984 |
Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.
Topics: Agranulocytosis; Amikacin; Bacterial Infections; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fever; Hearing Loss; Humans; Kanamycin; Kidney; Kinetics; Moxalactam; Neoplasms; Piperacillin; Ticarcillin | 1982 |
22 other study(ies) available for moxalactam and amikacin
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Genetic; Turkey | 2008 |
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
Topics: Acinetobacter baumannii; beta-Lactamases; DNA, Bacterial; Escherichia coli; France; Genes, Bacterial; Water Microbiology | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interactions of antimicrobial combinations in vitro: the relativity of synergism.
Topics: Amikacin; Azlocillin; Ceftazidime; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Escherichia coli; Imipenem; Klebsiella pneumoniae; Moxalactam; Netilmicin; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus | 1990 |
Enhanced in-vitro bactericidal activity of amikacin combined with latamoxef, cefotaxime and aztreonam against multi-resistant Enterobacter cloacae.
Topics: Amikacin; Aztreonam; beta-Lactamases; Cefotaxime; Drug Resistance, Microbial; Enterobacter; Enterobacteriaceae; Microbial Sensitivity Tests; Moxalactam; Time Factors | 1989 |
In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Azlocillin; Ceftazidime; Drug Combinations; Drug Synergism; Escherichia coli; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Moxalactam; Netilmicin; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins | 1986 |
In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefsulodin; Clindamycin; Drug Combinations; Drug Synergism; Enoxacin; Enterobacteriaceae; Microbial Sensitivity Tests; Moxalactam; Naphthyridines; Oxacillin; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Vancomycin | 1987 |
Increased minimum inhibitory concentrations with anaerobiasis for tobramycin, gentamicin, and amikacin, compared to latamoxef, piperacillin, chloramphenicol, and clindamycin.
Topics: Amikacin; Aminoglycosides; Anaerobiosis; Anti-Bacterial Agents; Chloramphenicol; Clindamycin; Enterobacter; Escherichia coli; Gentamicins; Humans; Klebsiella; Microbial Sensitivity Tests; Moxalactam; Piperacillin; Salmonella; Serratia; Staphylococcus; Streptococcus; Tobramycin | 1985 |
Interaction of third generation cephalosporins combined with amikacin against Pseudomonas aeruginosa.
Topics: Amikacin; Cefoperazone; Cefotaxime; Ceftizoxime; Cephalosporins; Drug Synergism; Kanamycin; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa | 1985 |
[Comparison of the in vitro activity of amikacin, netilmicin, piperacillin and moxalactam against Acinetobacter calcoaceticus var. anitratum].
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Microbial Sensitivity Tests; Moxalactam; Netilmicin; Piperacillin | 1985 |
In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Cefoxitin; Cephalothin; Cephamycins; Drug Resistance, Microbial; Enterobacteriaceae; Kanamycin; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa | 1982 |
Successful treatment of gram-negative bacillary meningitis with moxalactam.
Topics: Amikacin; Cephalosporins; Cephamycins; Enterobacteriaceae Infections; Humans; Male; Meningitis; Middle Aged; Moxalactam | 1982 |
Moxalactam/amikacin versus ticarcillin/amikacin in granulocytopenic patients.
Topics: Agranulocytosis; Amikacin; Cephalosporins; Cephamycins; Drug Therapy, Combination; Humans; Infections; Kanamycin; Moxalactam; Penicillins; Ticarcillin | 1983 |
Plasmid-independent resistance of 'gray' colony variants of a strain of Serratia marcescens resistant to amikacin, cefotaxime and lamoxactam.
Topics: Amikacin; Anti-Bacterial Agents; Cefotaxime; Cephamycins; Culture Media; DNA, Bacterial; Drug Resistance, Microbial; Moxalactam; Plasmids; Serratia marcescens | 1983 |
In vitro activity of newer beta-lactam agents in combination with amikacin against Pseudomonas aeruginosa, Klebsiella pneumoniae, and Serratia marcescens.
Topics: Amikacin; Anti-Bacterial Agents; Cefoperazone; Cefotaxime; Ceftazidime; Ceftizoxime; Cephalosporins; Drug Synergism; Imipenem; Kanamycin; Klebsiella pneumoniae; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa; Serratia marcescens; Thienamycins | 1983 |
Serratia marcescens pyarthrosis and osteomyelitis.
Topics: Adult; Amikacin; Amphetamine; Arthritis, Infectious; Combined Modality Therapy; Debridement; Drug Therapy, Combination; Enterobacteriaceae Infections; Humans; Male; Moxalactam; Osteomyelitis; Serratia marcescens; Substance-Related Disorders; Suppuration | 1984 |
Postantibiotic effect of imipenem on Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Imipenem; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa; Thienamycins; Time Factors | 1984 |
In vitro studies of moxalactam (LY127935), a new beta-lactam antibiotic with significant activity against gram-negative bacteria.
Topics: Amikacin; Ampicillin; Carbenicillin; Cefoxitin; Cefuroxime; Cephalosporins; Cephamycins; Clindamycin; Gram-Negative Aerobic Bacteria; Gram-Negative Anaerobic Bacteria; Haemophilus influenzae; Moxalactam; Oxacillin | 1980 |
Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.
Topics: Amikacin; Bacteria; Carbenicillin; Cefazolin; Cephalosporins; Cephamycins; Culture Media; Humans; Microbial Sensitivity Tests; Moxalactam; Penicillins; Piperacillin; Sepsis; Species Specificity; Ticarcillin; Tobramycin | 1980 |
Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amikacin; Bacteria, Anaerobic; Bacterial Infections; Child; Drug Evaluation; Drug Therapy, Combination; Enterobacteriaceae Infections; Female; Fever; Gram-Positive Bacteria; Humans; Infusions, Parenteral; Kanamycin; Male; Microbial Sensitivity Tests; Middle Aged; Moxalactam; Piperacillin; Pseudomonas Infections; Random Allocation; Staphylococcal Infections | 1984 |
Hemophagocytic syndrome associated with Bacteroides fragilis infection in a patient with acute monoblastic leukemia.
Topics: Amikacin; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacteroides fragilis; Bacteroides Infections; Ceftazidime; Cytarabine; Daunorubicin; Drug Therapy, Combination; Fatal Outcome; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Leukemia, Monocytic, Acute; Middle Aged; Moxalactam; Tonsillitis; Vancomycin | 1996 |